Anti-IL-12

2 trials

Sponsors

Centocor B.V., Centocor BV

Conditions

Moderate to Severe Plaque Psoriasis MedDRA version: 8.1 Level: LLT Classification code 10037153 Term: PsoriasisModerately to Severely Active Crohn’s Disease MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease

Unknown Phase

A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis

Active, not recruitingEUCTR2006-003444-30-FI

Centocor B.V.Moderate to Severe Plaque Psoriasis MedDRA version: 8.1 Level: LLT Classification code 10037153 Term: Psoriasis

Start: 2007-05-15Target: 650Updated: 2012-03-19

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Previously Treated with TNF Antagonist Therapy - CERTIFI

Active, not recruitingEUCTR2008-000649-77-NL

Centocor BVModerately to Severely Active Crohn’s Disease MedDRA version: 9.1 Level: LLT Classification code 10011401 Term: Crohn's disease

Start: 2009-02-06Target: 500Updated: 2012-03-19